与抗抑郁药相关的不节律事件:贝叶斯不成比例分析挖掘FDA不良事件报告系统数据库
Shan Cao1, Zhuoshan Huang1, Wenjie Yang2
1Department of Cardiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Frontiers in psychiatry
|October 15, 2025
概括
选择性血清素再吸收抑制剂,如西塔洛普拉姆和埃斯基塔洛普拉姆,与心律失常有很强的联系. 其他抗抑郁药物,如芬拉法辛和杜洛西丁,风险较低,需要进一步研究.
科学领域:
- 药物监督 药物监督 药物监督
- 心脏病学 心脏病学
- 心理药理学 心理药理学
背景情况:
- 抗抑郁药被广泛用于治疗抑郁症.
- 了解它们的潜在心血管风险,特别是心律失常,对于患者的安全至关重要.
- 美国食品和药物管理局的不良事件报告系统 (FAERS) 是药物监测的宝贵资源.
研究的目的:
- 为了调查与抗抑郁药物相关的心律失常事件的药物监测信号.
- 对特定抗抑郁药在心律失常方面的风险和结果进行对对比.
主要方法:
- 对2015年第一季度至2023年第三季度用于抑郁症抗抑郁药的FAERS数据的分析.
- 专注于主要终点:QT延长/Torsades de Pointes (TdP),心房动 (AF),心脏阻塞和心室节律失常的药物监测.
- 二级终点:对药物特异性比率和结果严重性的对对比.
主要成果:
- 用于QT延长/TdP的药监监测发现了利,埃斯基塔洛普拉姆,西和奎蒂亚平.
- 对于citalopram,escitalopram,sertraline和fluoxetine检测到的心房的信号.
- 找到了citalopram和mirtazapine的心脏阻塞信号.
- 对于西塔洛普拉姆,埃斯基塔洛普拉姆和奎蒂阿平,观察到的心室心律失常信号.
结论:
- 西塔洛普拉姆和埃斯基塔洛普拉姆 (SSRI) 显示出与心律失常的最强相关性.
- 奎蒂亚平 (SGA) 对QT延长/TdP和心室节律失常的风险更高.
- 文拉法辛和杜洛西丁 (SNRIs) 没有显示心律失常的药监信号,表明潜在的风险较低.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Disturbances in Heart Rhythm
2.5K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
2.5K
Dysrhythmias V: Evaluating Dysrhythmias
328
Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
328
Antidepressant Drugs: Overview
1.4K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.4K
Dysrhythmias VI: Management of Dysrhythmias
431
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
431


